1. Home
  2. |Insights
  3. |EEO-1 Reports Due March 31st

EEO-1 Reports Due March 31st

Client Alert | 1 min read | 03.14.18

As we enter the Ides of March, a reminder to all employers with 100 or more employees, and all government contractors/first-tier subcontractors with 50 or more employees and a contract of at least $50,000, that the 2017 EEO-1 report must be filed by March 31, 2018. 

2017 revisions to the EEO-1 Report changed the annual filing date from September 30 to March 31, and would have required employers to submit compensation and hours data in addition to the standard workforce representation data.  Employers received a reprieve from the compensation and hours data obligations in August 2017 when the Office of Management and Budget issued a stay of those portions of the revised Report.  The change to the filing deadline, however, remained in place.  As such, employers must now use a payroll period between October 1 and December 31, 2017 as the basis for the submission, and must file their 2017 EEO-1 Report by March 31, 2018. 

So for those who were used to filing in the Fall, and may not have the filing date on their Spring calendars, don’t forget to submit by the March 31 deadline. 

Contacts

Insights

Client Alert | 9 min read | 10.21.26

Artificial Intelligence in Life Sciences: Reliability of AI-Generated Evidence in Drug Discovery and Development

The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .  ...